SAN DIEGO--(BUSINESS WIRE)--Pathway Genomics Corporation (“Pathway”) today announced a settlement agreement that ends the BRCA patent litigation against Pathway that began on June 13, 2014. Under the agreement, Myriad Genetics, Inc., the University of Utah Research Foundation, HSC Research and Development Limited Partnership, Endorecherche, Inc., and the Trustees of the University of Pennsylvania (the “Patent Owners”) and Pathway dismiss their respective claims and counterclaims against one another in the BRCA patent litigation. Additionally, the Patent Owners granted a covenant to not sue Pathway under the patents asserted in the litigation proceedings.
Help employers find you! Check out all the jobs and post your resume.
